Vericel Confident in Near-Term MACI Recovery

By Mike Evers

Vericel Confident in Near-Term MACI Recovery
Vericel’s MACI revenue grew 22% in 1Q20 despite mid-March disruptions from COVID-19. The company believes it has passed the market low point and remains confident it will recoup most lost procedures.

Member-Only Content

SUBSCRIBE Login

Product Labels: Orthobiologic Soft Tissue Repair

Tags: Revenue Report